Everence Capital Management Inc. Sells 3,280 Shares of Glaukos Co. (NYSE:GKOS)

Everence Capital Management Inc. decreased its stake in Glaukos Co. (NYSE:GKOS) by 46.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,820 shares of the medical instruments supplier’s stock after selling 3,280 shares during the quarter. Everence Capital Management Inc.’s holdings in Glaukos were worth $573,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Values First Advisors Inc. bought a new stake in shares of Glaukos in the third quarter worth about $25,000. Harvest Fund Management Co. Ltd grew its position in Glaukos by 2,263.2% in the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after purchasing an additional 860 shares in the last quarter. KBC Group NV increased its stake in Glaukos by 16.2% in the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after buying an additional 201 shares during the last quarter. EWA LLC bought a new stake in Glaukos during the 3rd quarter worth about $209,000. Finally, Procyon Advisors LLC acquired a new position in shares of Glaukos during the 3rd quarter worth about $210,000. Institutional investors own 99.04% of the company’s stock.

Glaukos Stock Performance

Shares of NYSE:GKOS opened at $151.45 on Friday. The company’s 50 day simple moving average is $142.09 and its 200 day simple moving average is $130.72. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. Glaukos Co. has a 1 year low of $75.90 and a 1 year high of $153.50. The stock has a market capitalization of $8.35 billion, a price-to-earnings ratio of -50.15 and a beta of 1.03.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.20. The business had revenue of $96.70 million during the quarter, compared to the consensus estimate of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. Glaukos’s revenue for the quarter was up 23.9% on a year-over-year basis. During the same period in the prior year, the company earned ($0.50) EPS. As a group, research analysts predict that Glaukos Co. will post -1.89 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Gilbert H. Kliman sold 2,000 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total transaction of $288,020.00. Following the sale, the director now owns 32,336 shares of the company’s stock, valued at $4,656,707.36. This trade represents a 5.82 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Joseph E. Gilliam sold 3,328 shares of the company’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $149.85, for a total value of $498,700.80. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $15,310,024.65. The trade was a 3.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 17,603 shares of company stock worth $2,605,678 in the last three months. 6.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have weighed in on GKOS. JPMorgan Chase & Co. raised their price target on Glaukos from $130.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Stifel Nicolaus increased their price target on shares of Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, December 31st. UBS Group assumed coverage on shares of Glaukos in a research note on Friday, December 6th. They set a “buy” rating and a $182.00 price objective on the stock. StockNews.com upgraded shares of Glaukos from a “sell” rating to a “hold” rating in a research note on Monday, October 21st. Finally, Truist Financial upped their price objective on Glaukos from $152.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Glaukos has an average rating of “Moderate Buy” and a consensus target price of $147.75.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.